Thiazovivin (Synonyms: Tzv) |
Catalog No.GC11181
One-Click Copy Product Info
|
Thiazovivin es un inhibidor selectivo de la quinasa asociada a Rho (ROCK)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1226056-71-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Thiazovivin es un inhibidor selectivo de la quinasa asociada a Rho (ROCK) [1]. Thiazovivin inhibe selectivamente la vías de señalización ROCK, reduce la tensión citoesquelética, reduce la apoptosis celular inducida por el estrés, promueve la adhesión y propagación celular y, por lo tanto, mejora la supervivencia celular en un estado unicelular [2-3]. Thiazovivin se utiliza a menudo en la investigación de células madre y la ingeniería celular [4].
En las células endoteliales corneales humanas (HCEC), Thiazovivin (2µM, 4µM, 6µM; 24h, 48h) mejora la morfología de la HCEC, las uniones celulares y la expresión del transportador de iones al inhibir EndMT/EMT [5]. En las células madre embrionarias humanas el tratamiento con Thiazovivin (2µM; 24h) mejora el mantenimiento del tallo en poblaciones putativas de células madre de ganado al promover la expresión de los genes marcadores de pluripotencia, así como mejorar la expresión del gen E-cadherin, lo que resulta en un aumento en la adhensión celular [1]. En las células endoteliales corneales humanas, el tratamiento con Thiazovivin (2µM, 4µM, 6µM; 24h) mejoró la morfología, conectividad y función celular, e inhibió significativamente la expresión de la proteína ROCK[6]. En embriones bovinos, el tratamiento con Thiazovivin (2µM; 96h) mejora la supervivencia embrionaria y las tasas de eclosión [7]. En las células musculares lisas humanas, Thiazovivin (2µM; 2h) revierte la fosforilación inducida por AngII de MYPT1 y MLC [8].
References:
[1]. Park S, Kim D, Jung YG, et al. Thiazovivin, a Rho kinase inhibitor, improves stemness maintenance of embryo-derived stem-like cells under chemically defined culture conditions in cattle. Animal reproduction science. 2015 Oct 1; 161: 47-57.
[2]. Mohseni R, Shoae‐Hassani A, Verdi J. Reprogramming of endometrial adult stromal cells in the presence of a ROCK inhibitor, thiazovivin, could obtain more efficient iPSCs. Cell biology international. 2015 May; 39(5): 515-518.
[3]. Laowtammathron C, Chingsuwanrote P, Srisook P, et al. The novel combination of small-molecule inhibitors increases the survival and colony formation capacity of human induced pluripotent stem cells after single-cell dissociation. Science Progress. 2025 Apr; 108(2): 00368504251330956.
[4]. Rizzino A. Stimulating progress in regenerative medicine: improving the cloning and recovery of cryopreserved human pluripotent stem cells with ROCK inhibitors. Regenerative medicine. 2010 Sep 1; 5(5): 799-807.
[5]. Wu Q, Ouyang C, Xie L, et al. The ROCK inhibitor, thiazovivin, inhibits human corneal endothelial‑to‑mesenchymal transition/epithelial‑to‑mesenchymal transition and increases ionic transporter expression. International journal of molecular medicine. 2017 Oct 1; 40(4): 1009-1018.
[6]. Wu QN, Ling YZ, Ouyang C, et al. Effect of a new ROCK inhibitor thiazovivin on the morphology and function of human corneal endothelial cells. [Zhonghua yan ke za Zhi] Chinese Journal of Ophthalmology. 2016 Sep 1; 52(9): 686-692.
[7]. Kim D, Sul H, Jung YG, et al. Holding of bovine blastocysts at suprazero temperatures using small molecules. Scientific Reports. 2017 Aug 25; 7(1): 9490.
[8]. Cao X, Luo T, Luo X, et al. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertension Research. 2014 Sep; 37(9): 803-810.
| Experimentos celulares [1]: | |
Líneas celulares | Células endoteliales corneales humanas (HCEC) |
Método de preparación | Las HCEC primarias y de paso se cultivaron, y las células se identificaron observando la morfología celular bajo un microscopio de luz y a través de experimentos de tinción de inmunofluorescencia NSE. Cuando la confluencia de células primarias estaba cerca del 70%-80%, se añadió un 0,25% de tripsina-EDTA (1X) para la digestión. Después de la centrifugación, las células fueron subcultivadas (1-3 generaciones). Los HCEC primarios y de paso se cultivaron en placas de cultivo de cámara de 8 pozos. Cuando la confluencia celular alcanzó aproximadamente el 80 %, se añadieron varias concentraciones de tiazovina (2, 4 y 6 µM), DMSO al 0,6 % o 10 µM Y-27632. |
Condiciones de reacción | 2 µM, 4µM, 6µM; 24h, 48h |
Áreas de aplicación | La tiazovivina mejora la morfología de la HCEC, las uniones celulares y la expresión del transportador iónico inhibiendo EndMT/EMT. |
References: | |
| Cas No. | 1226056-71-8 | SDF | |
| Sinónimos | Tzv | ||
| Chemical Name | N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide | ||
| Canonical SMILES | C1=CC=C(C=C1)CNC(=O)C2=CSC(=N2)NC3=NC=NC=C3 | ||
| Formula | C15H13N5OS | M.Wt | 311.36 |
| Solubility | ≥ 15.55mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2117 mL | 16.0586 mL | 32.1172 mL |
| 5 mM | 642.3 μL | 3.2117 mL | 6.4234 mL |
| 10 mM | 321.2 μL | 1.6059 mL | 3.2117 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)